By Market Intelligence Team

AppliedVR, which creates immersive virtual reality therapeutics, announced $36 million in series B funding, bringing its total funding to $71 million. AppliedVR recently received approval from the U.S. Food and Drug Administration (FDA) for its first de novo submission. AppliedVR's flagship product for chronic pain recently became the first virtual reality (VR) prescription therapeutic to receive FDA Breakthrough Device Designation for treatment-resistant fibromyalgia and chronic intractable lower back pain. The round included investments from F-Prime Capital, JAZZ Venture Partners, Sway Ventures and SVB Ventures. Founded in 2015, AppliedVR, the company develops immersive therapeutics are effective and usable for patients, scalable…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!